Andrea Leiva1, Camila Diez de Medina, Rocío Salsoso, Tamara Sáez, Sebastián San Martín, Fernando Abarzúa, Marcelo Farías, Enrique Guzmán-Gutiérrez, Fabián Pardo, Luis Sobrevia. 1. From the Cellular and Molecular Physiology Laboratory, Division of Obstetrics and Gynaecology, School of Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile (A.L., C.D.d.M., R.S., T.S., F.A., M.F., E.G.-G., F.P., L.S.); Biomedical Research Centre, Department of Biomedical Sciences, School of Medicine, Universidad de Valparaíso, Valparaíso, Chile (S.S.M.); Obstetrics and Gynecology Unit, Clínica Alemana, Temuco, Chile (F.A.); and the University of Queensland Centre for Clinical Research, Faculty of Health Sciences, The University of Queensland, Herston, Queensland, Australia (L.S.).
Abstract
OBJECTIVE: Human pregnancy that courses with maternal supraphysiological hypercholesterolemia (MSPH) correlates with atherosclerotic lesions in fetal arteries. It is known that hypercholesterolemia associates with endothelial dysfunction in adults, a phenomenon where nitric oxide (NO) and arginase are involved. However, nothing is reported on potential alterations in the fetoplacental endothelial function in MSPH. The aim of this study was to determine whether MSPH alters fetal vascular reactivity via endothelial arginase/urea and L-arginine transport/NO signaling pathways. APPROACH AND RESULTS: Total cholesterol <280 mg/dL was considered as maternal physiological hypercholesterolemia (n=46 women) and ≥ 280 mg/dL as MSPH (n=28 women). Maternal but not fetal total cholesterol and low-density lipoprotein-cholesterol levels were elevated in MSPH. Umbilical veins were used for vascular reactivity assays (wire myography), and primary cultures of umbilical vein endothelial cells to determine arginase, endothelial NO synthase (eNOS), and human cationic amino acid transporter 1 and human cationic amino acid transporter 2A/B expression and activity. MSPH reduced calcitonine gene-related peptide-umbilical vein relaxation and increased intima/media ratio (histochemistry), as well as reduced eNOS activity (L-citrulline synthesis from L-arginine, eNOS phosphorylation/dephosphorylation), but increased arginase activity and arginase II protein abundance. Arginase inhibition increased eNOS activity and L-arginine transport capacity without altering human cationic amino acid transporter 1 or human cationic amino acid transporter 2A/B protein abundance in maternal physiological hypercholesterolemia and MSPH. CONCLUSIONS: MSPH is a pathophysiological condition altering umbilical vein reactivity because of fetal endothelial dysfunction associated with arginase and eNOS signaling imbalance. We speculate that elevated maternal circulating cholesterol is a factor leading to fetal endothelial dysfunction, which could have serious consequences to the growing fetus.
OBJECTIVE:Human pregnancy that courses with maternal supraphysiological hypercholesterolemia (MSPH) correlates with atherosclerotic lesions in fetal arteries. It is known that hypercholesterolemia associates with endothelial dysfunction in adults, a phenomenon where nitric oxide (NO) and arginase are involved. However, nothing is reported on potential alterations in the fetoplacental endothelial function in MSPH. The aim of this study was to determine whether MSPH alters fetal vascular reactivity via endothelial arginase/urea and L-arginine transport/NO signaling pathways. APPROACH AND RESULTS: Total cholesterol <280 mg/dL was considered as maternal physiological hypercholesterolemia (n=46 women) and ≥ 280 mg/dL as MSPH (n=28 women). Maternal but not fetal total cholesterol and low-density lipoprotein-cholesterol levels were elevated in MSPH. Umbilical veins were used for vascular reactivity assays (wire myography), and primary cultures of umbilical vein endothelial cells to determine arginase, endothelial NO synthase (eNOS), and human cationic amino acid transporter 1 and human cationic amino acid transporter 2A/B expression and activity. MSPH reduced calcitonine gene-related peptide-umbilical vein relaxation and increased intima/media ratio (histochemistry), as well as reduced eNOS activity (L-citrulline synthesis from L-arginine, eNOS phosphorylation/dephosphorylation), but increased arginase activity and arginase II protein abundance. Arginase inhibition increased eNOS activity and L-arginine transport capacity without altering human cationic amino acid transporter 1 or human cationic amino acid transporter 2A/B protein abundance in maternal physiological hypercholesterolemia and MSPH. CONCLUSIONS: MSPH is a pathophysiological condition altering umbilical vein reactivity because of fetal endothelial dysfunction associated with arginase and eNOS signaling imbalance. We speculate that elevated maternal circulating cholesterol is a factor leading to fetal endothelial dysfunction, which could have serious consequences to the growing fetus.
Authors: F Pardo; L Silva; T Sáez; R Salsoso; J Gutiérrez; C Sanhueza; A Leiva; L Sobrevia Journal: Int J Obes (Lond) Date: 2015-04-14 Impact factor: 5.095
Authors: Jerad H Dumolt; Sandhya K Radhakrishnan; Mohammed H Moghadasian; Khuong Le; Mulchand S Patel; Richard W Browne; Todd C Rideout Journal: J Nutr Biochem Date: 2017-09-28 Impact factor: 6.048
Authors: Luiza A Rabelo; Fernanda O Ferreira; Valéria Nunes-Souza; Lucas José Sá da Fonseca; Marília O F Goulart Journal: Oxid Med Cell Longev Date: 2015-05-04 Impact factor: 6.543
Authors: Felipe A Zuniga; Valeska Ormazabal; Nicolas Gutierrez; Valeria Aguilera; Claudia Radojkovic; Carlos Veas; Carlos Escudero; Liliana Lamperti; Claudio Aguayo Journal: Biomed Res Int Date: 2014-07-06 Impact factor: 3.411